Alnylam Pharmaceuticals (ALNY) Net Margin (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) reported Net Margin of 17.65% for Q1 2026, up 7849.0% on a YoY basis from 0.22% in Q1 2025, and up 73.58% quarter-over-quarter from 10.17% in Q4 2025.
Alnylam Pharmaceuticals (ALNY) Net Margin (2009 - 2026) Analysis & Trends
Alnylam Pharmaceuticals has reported Net Margin for 18 years, with the latest figure at 17.65% in Q1 2026.
- For the quarter ending Q1 2026, Net Margin rose 7849.0% year-over-year to 17.65%; the trailing twelve-month figure through Mar 2026 stood at 12.69% (up 2561.0% YoY), and the FY2025 full-year result was 8.45%, up 2082.0% from the prior year.
- Net Margin for Q1 2026 stood at 17.65%, up from 10.17% in the prior quarter.
- The five-year high for Net Margin was 23.43% in Q3 2025, with the low at 153.58% in Q3 2022.
- Historically, Net Margin has averaged 39.7% across 5 years, with a median of 22.27% in 2024.
- Annual changes were most pronounced in 2023 — Net Margin surged 17327 bps — and 2025, when it sank 4750 bps.
- Alnylam Pharmaceuticals' Net Margin stood at 61.93% in 2022, then soared by 49 bps to 31.35% in 2023, then soared by 55 bps to 14.12% in 2024, then soared by 172 bps to 10.17% in 2025, then surged by 74 bps to 17.65% in 2026.
- The last three Net Margin figures came in at 17.65% (Q1 2026), 10.17% (Q4 2025), and 23.43% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 0.82% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 34.53% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Alnylam Pharmaceuticals | 37.04 Bn | 34.03 Bn | 959.66 Mn | 17.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.65% |
| Dec 31, 2025 | 10.17% |
| Sep 30, 2025 | 23.43% |
| Jun 30, 2025 | -8.57% |
| Mar 31, 2025 | -60.84% |
| Dec 31, 2024 | -14.12% |
| Sep 30, 2024 | -22.27% |
| Jun 30, 2024 | -2.56% |
| Mar 31, 2024 | -13.34% |
| Dec 31, 2023 | -31.35% |
| Sep 30, 2023 | 19.69% |
| Jun 30, 2023 | -86.59% |
| Mar 31, 2023 | -54.53% |
| Dec 31, 2022 | -61.93% |
| Sep 30, 2022 | -153.58% |
| Jun 30, 2022 | -123.39% |
| Mar 31, 2022 | -112.70% |
| Dec 31, 2021 | -99.97% |
| Sep 30, 2021 | -109.00% |
| Jun 30, 2021 | -85.95% |